EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study

Yujie Zhao, Jacqueline T Ferri, James R White, Megan D Schollenberger, Kim Peloza, Cynthia L Sears iD, Evan J Lipson, Fyza Y Shaikh iD

Microbiology Spectrum · 04.03.2025 · 13 (3)

DOI: 10.1128/spectrum.02559-24 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, erschienen am 04.03.2025. Verfasst von Yujie Zhao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA. Hauptthemen laut MEDLINE: Gastrointestinal Microbiome, Immune Checkpoint Inhibitors, Skin Neoplasms, Bacteria. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Marilyn and Michael Grossman Fund for Basal Cell Carcinoma and Melanoma Research, JHU | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University | Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Ca…, NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Immune checkpoint inhibitor (ICI) therapy has yielded revolutionary outcomes among some individuals with skin cancer, but a large percentage of individuals do not benefit from these treatments. The gut microbiota is hypothesized to impact ICI therapy outcomes. However, data on ICI therapy, gut microbiota, and non-melanoma skin cancers are limited. To examine the association of gut microbiota structure and function with non-melanoma skin cancer ICI outcomes, we performed 16S rRNA V1-V2 gene amplicon sequencing of 68 fecal samples collected longitudinally from individuals with basal cell carcinoma ( n = 5), Merkel cell carcinoma ( n = 5), or cutaneous squamous cell carcinoma (CSCC, n = 11), followed by tumor-dependent differential analyses of bacterial composition and fecal sample analysis by untargeted metabolomics. Across all tumor types, we identified 10 differential bacterial genera between responders (R) or non-responders (NR) to ICI therapy. Among individuals with CSCC, we identified 10 genera and 20 species that differentiated between R and NR and yielded 8 pathways enriched in NR and 12 pathways enriched in R by predicted functional pathway analyses. Untargeted fecal metabolomics to examine putative gut microbiota metabolites associated with CSCC ICI R/NR identified nine KEGG pathways associated with ICI efficacy. In summary, this exploratory study suggests gut microbiota features that are associated with ICI efficacy in individuals with non-melanoma skin cancers and highlights the need for larger studies to validate the results. IMPORTANCE Prior studies examining associations between ICI efficacy and the gut microbiome have focused primarily on individuals with melanoma, for whom ICI therapy was first approved. Meanwhile, data regarding microbiome features associated with ICI responses in individuals with non-melanoma skin cancers (NMSCs) have remained limited. This initial fecal microbiota examination of individuals with NMSCs suggests that larger-scale studies to extend and validate our findings may yield predictive or prognostic biomarkers for individuals with NMSC receiving ICI with potential to provide insight to complementary, effective therapeutic interventions through microbiota modification.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastrointestinal MicrobiomeImmune Checkpoint InhibitorsSkin NeoplasmsBacteriaHumansFecesMaleFemaleBasal Cell CarcinomaMiddle AgedAgedRNA, Ribosomal, 16SCarcinoma, Squamous CellCarcinoma, Merkel CellMetabolomicsAged, 80 and over

Stichwörter der Autor:innen

Merkel cell carcinomabasal cell carcinomacutaneous squamous cell carcinomaimmune checkpoint inhibitorsmicrobiome

Substanzen

Immune Checkpoint InhibitorsRNA, Ribosomal, 16S

Autor:innen und Institutionen

  • Department of Biomedical Engineering, Johns Hopkins University, Baltimore, Maryland, USA.
  • Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • Resphera Biosciences, Baltimore, Maryland, USA.
  • Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA.
  • The Bloomberg~Kimmel Institute for Cancer Immunotherapy, Baltimore, Maryland, USA.

ORCID-Profile: Cynthia L Sears, Fyza Y Shaikh

Förderung

  • The Marilyn and Michael Grossman Fund for Basal Cell Carcinoma and Melanoma Research
  • JHU | Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University | Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Ca…
  • NCI NIH HHS
  • HHS | NIH | National Cancer Institute (NCI)
  • Damon Runyon Cancer Research Foundation (DRCRF)
  • Bristol Myers Squibb Foundation (BMSF)

Zitieren

APA

Zhao, Y., Ferri, J. T., White, J. R., Schollenberger, M. D., Peloza, K., Sears, C. L., Lipson, E. J., & Shaikh, F. Y. (2025). Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study. Microbiology Spectrum, 13(3). https://doi.org/10.1128/spectrum.02559-24

Vancouver

Zhao Y, Ferri JT, White JR, Schollenberger MD, Peloza K, Sears CL, et al. Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study. Microbiology Spectrum. 2025;13(3). doi:10.1128/spectrum.02559-24

BibTeX
@article{Zhao2025,
  author = {Zhao, Yujie and Ferri, Jacqueline T and White, James R and Schollenberger, Megan D and Peloza, Kim and Sears, Cynthia L and Lipson, Evan J and Shaikh, Fyza Y},
  title = {Gut microbiome features associate with immune checkpoint inhibitor response in individuals with non-melanoma skin cancers: an exploratory study},
  journal = {Microbiology Spectrum},
  year = {2025},
  volume = {13},
  number = {3},
  doi = {10.1128/spectrum.02559-24}
}
Kostenlos starten →